Jefferies analyst Martin Comtesse maintained a Buy rating on Redcare Pharmacy today and set a price target of €150.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Martin Comtesse has given his Buy rating due to a combination of factors including the positive developments in Redcare Pharmacy’s financial performance. The company reported an adjusted EBITDA margin of 2.4% in the third quarter, which aligns with their target range of 2.0-2.5% for the fiscal year 2025. This achievement is seen as a positive indicator of the company’s operational efficiency and financial health.
Additionally, with only a short period left in the calendar year, the confirmation of fiscal year 2025 targets is expected to bolster investor confidence. The anticipated acceleration in prescription growth to over €150 million in the fourth quarter further supports the optimistic outlook. These elements combined suggest a promising trajectory for Redcare Pharmacy, justifying the Buy rating.
In another report released on October 23, Deutsche Bank also maintained a Buy rating on the stock with a €214.00 price target.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is neutral on the stock.